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Abstract
Purpose: The aim of that work is to study the theoretical behavior and merits of the Generalized Gamma (generalized dose re-
sponse gradient) as well as to investigate the usefulness of this concept in practical radiobiological treatment planning. Methods:
In this study, the treatment planning system RayStation 1.9 (Raysearch Laboratories AB, Stockholm, Sweden) was used. Fur-
thermore, radiobiological models that provide the tumor control probability (TCP), normal tissue complication probability
(NTCP), complication-free tumor control probability (P+) and the Generalized Gamma were employed. The Generalized Gammas
of TCP and NTCP, respectively were calculated for given heterogeneous dose distributions to different organs in order to verify
the TCP and NTCP computations of the treatment planning system. In this process, a treatment plan was created, where the
target and the organs at risk were included in the same ROI in order to check the validity of the system regarding the objective
function P+ and the Generalized Gamma. Subsequently, six additional treatment plans were created with the target organ and the
organs at risk placed in the same or different ROIs. In these plans, the mean dose was increased in order to investigate the be-
havior of dose change on tissue response and on Generalized Gamma before and after the change in dose. By theoretically cal-
culating these quantities, the agreement of different theoretical expressions compared to the values that the treatment planning
system provides could be evaluated. Finally, the relative error between the real and approximate response values using the
Poisson and the Probit models, for the case of having a target organ consisting of two compartments in a parallel architecture and
with the same number of clonogens could be investigated and quantified. Results: The computations of the RayStation regarding
the values of the Generalized Gamma and the objective function (P+) were verified by using an independent software. Further-
more, it was proved that after a small change in dose, the organ that is being affected most is the organ with the highest Gener-
alized Gamma. Apart from that, the validity of the theoretical expressions that describe the change in response and the associated
Generalized Gamma was verified but only for the case of small change in dose. Especially for the case of 50% TCP and NTCP, the
theoretical values (ΔPapprox.) and those calculated by the RayStation show close agreement, which proves the high importance of
the D50 parameter in specifying clinical response levels. Finally, the presented findings show that the behavior of ΔPapprox. looks
sensible because, for both of the models that were used (Poisson and Probit), it significantly approaches the real ΔP around the
region of 37% and 50% response. The present study managed to evaluate the mathematical expression of Generalized Gamma for
the case of non-uniform dose delivery and the accuracy of the RayStation to calculate its values for different organs. Conclusion:
A very important finding of this work is the establishment of the usefulness and clinical relevance of Generalized Gamma. That is
because it gives the planner the opportunity to precisely determine which organ will be affected most after a small increase in
dose and as a result an optimal treatment plan regarding tumor control and normal tissue complications can be found.
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Introduction
Recent technological developments have introduced dra-
matic changes in the field of Radiotherapy.1, 2 Radiological
imaging has become more advanced providing information at
functional level. In this way, a better assessment of the
spread, cell density and radiosensitivity variation of clono-
genic tumor cells can be accomplished.3 For normal tissues,
information on the location and distribution of radiation
sensitive functional subunits can be assessed.4, 5 Furthermore,
the possibility of calculating now the fractional and through
them the composite dose distributions delivered to the pa-
2 Petrou et al.: Evaluation of the generalized gamma International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Petrou et al. ISSN 2330-4049
tients in a 3-dimensional mode gives a better view of the
effectiveness of the applied treatment configurations.6, 7 This
abundance of information needs to be accurately used in
order to achieve a close agreement between treatment plan-
ning and clinical outcome.
Modern treatment planning algorithms try to maximize the
conformation of the delivered dose distribution to the target
volume through three-dimensional intensity modulated
treatment planning, which conforms the high dose region to
the shape of the target volume and takes into account the
location of the organs at risk (OAR).8-11 Commonly, the irra-
diation protocols apply dose prescriptions and constraints
that have been associated with certain clinically accepted
tumor control and normal tissue complication rates. In the
current practice, the mean dose in the target volume and
additional dose-volume points in the targets and organs at
risk are mainly used in treatment plan optimization as objec-
tive functions or constraints, respectively.
However, the clinical outcome of a radiotherapy treatment in
terms of tumor control and normal tissue complications is
nearly always linked to a degree of uncertainty.12, 13 This is
partly because two treatment fractions of the same beam
configuration are not exactly the same since the nature of
radiation beams are stochastic at a microscopic level. Fur-
thermore, the inter-patient and cellular radiosensitivity var-
iations are generally unknown. For these reasons, the ex-
pected outcome of a treatment is expressed as the probability
of having a certain treatment effect. Radiobiological treat-
ment planning estimates these probabilities for each target
and organ at risk of a given clinical case based on the applied
dose-distribution and radiobiological data.14-16
Currently, the standard tools that are used for radiotherapy
treatment plan evaluation (e.g. isodose distribution, dose
volume histogram (DVH), etc) are based on dose only and
they do not take the radiobiological characteristics of tumors
or normal tissues into account. To cover this gap, the concepts
of Tumor Control Probability (TCP), Normal Tissue Compli-
cation Probability (NTCP) and complication-free tumor
control (P+) were initially introduced to provide an additional
plan evaluation analysis.8 More recently, the quantities of the
Normalized Dose-response gradient and the Generalized
Dose-response gradient were proposed as a supplementary
tool in the optimization of treatment plans involving
non-uniform dose deliveries, respectively.17
The principle aim of this study is to investigate the theoretical
behavior and merits of the Generalized Gamma (generalized
dose response gradient) concept. The secondary goal is to
examine the usefulness and clinical relevance of the Gener-
alized Gamma in practical radiobiological treatment planning
through its implementation in the RayStation® treatment
planning system.
Methods and Materials
Definition of the Generalized Gamma
The normalized dose-response gradient was introduced in the
80s (Brahme 1984) and it has extensively been used for de-
scribing the dose-response relations of both tumors and
normal tissues.18 The normalized dose-response gradient γ(D)
can be defined at any dose level D according to the following
expression:


 dD
DdPDD )()( --------------------------Eq. 1
where, P(D) is the response of the examined tissue to a given
dose, D. The most useful features of γ is that it can be used to
predict the change in response from a small change in dose
according to the following formula:
D
DDP  )( ----------------------------Eq. 2
From a clinical and radiobiological point of view, it has al-
ways been important to know the value of the steepest gra-
dient of the dose-response relationship. This value is denoted
as~ and is defined as follows:
)~(~~ DPD  , where
D
DPDP D 
 )(max)~( -----------Eq. 3
In 2001, the concept of the normalized dose-response gradi-
ent was generalized to account for non-uniform dose deliv-
ery, 17 by explicitly extending the definition of γ as a function
of a 3-dimensional dose distribution DrD  )( and by re-
placing the derivative in Equation (1) with a gradient as
shown below:
)()( DPDD D

 ----------------------Eq. 4
This definition makes it possible to calculate the normalized
dose-response gradients of different tumors and healthy tis-
sues receiving a given dose distribution and to relate them to
various clinical endpoints. The magnitude of the different γ
values gives the planner a hint about the modification of the
dose distribution needed in order to most effectively decrease
normal tissue complications and maximize the probability of
complication free cure.
Mathematical formulae related to dose-response
gradient
One of the radiobiological models that have extensively been
used to describe the dose-response relation of tumors and
normal tissues is the linear-quadratic model, which is given
by the following mathematical expression:
    / ln ln 250( ) exp e D D eP D e      -----------Eq. 5
where D50, which is the dose that produces a given response
to 50% of the patients and γ, which is the maximum nor-
malized gradient of the dose-response curve.4, 15, 19 In order to
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calculate the normal tissue complication probability (NTCP)
of an OAR to a given heterogeneous dose distribution, the
relative seriality model was used:4, 15, 20, 21
1/
1
( , ) 1 (1 ( ) ) i
sM Vs
I i
i
P D V P D 

     
  ----------------Eq. 6
where, M is the total number of voxels or subvolumes in the
tissue, ΔVi is the fractional irradiated subvolume of an organ
compared to the reference volume, Vref for which the values
of D50 and γ were calculated and s is the relative seriality
parameter that characterizes the internal organization of the
organ. P(Di) is the probability of response of the organ having
reference volume and being irradiated to dose Di as described
by Equation (5).
Regarding the calculation of the TCP it is assumed that the
tumor has a parallel structural organization since the eradi-
cation of all the clonogenic cells is required. This prerequisite
is satisfied by the following relationship:15
1
( , ) ( ) iM Vi
i
P D V P D 

 ---------------Eq. 7
Finally, regarding the calculation of the Generalized Gamma,
the following relationship was used:
1 1
( ) ( )( ) ( ) n niD i i
i ii i i
PP D P DD D P D D P D P  
        ---- Eq. 8
where,Di is the quasi-uniform dose in voxel i and γi is the local
contribution of voxel i to the Generalized Gamma and it is
given by the following equation:
( ) ii i i
i
PD D D 
  
--------------------Eq. 9
Treatment planning specification and optimization by
using RayStation
The platform that was used for conducting the present study
is RayStation 1.9 (Raysearch Laboratories AB, Sweden).
RayStation is among the few treatment planning systems that
can produce treatment plans combining different radiation
modalities and optimize them using radiobiological measures
such as the Generalized Gamma.
In this study, data from prostate cancer cases were used. So,
the target of the examined treatment plans was the prostate
region and the optimization algorithm calculated the value of
the Generalized Gamma for this target while optimizing the
plan. During this process, the number of beams, their energy
and portals as well as the overall geometry of the treatment
configuration were specified. More specifically, the MLC Step
and Shoot IMRT radiation modality was used in all the plans.
Three 6MV beams were used (gantry angles: 72, 180 and 288
degrees) to achieve an acceptable treatment plan. The dose
prescription and number of fractions in every plan were
determined by the optimal P+ value, whereas the predeter-
mined dose per fraction was 2.0 Gy. The primary organs at
risk (OAR) involved in this case are bladder and rectum. Also,
for the different goals of the study, different regions of in-
terest (ROI) were defined. A number of measures were used
as evaluators of the quality of the treatment plan such as the
minimum dose to the target (Dmin), maximum doses to the
OARs (Dmax, which corresponds to D1cc) as well as dose vol-
ume histogram (DVH) constraints. Furthermore, radiobio-
logical measures such as the Tumor Control Probability
(TCP), the Normal Tissue Compatibility Probability (NTCP)
and the complication-free tumor control probability (P+)
were employed. The TCP function corresponds to the prob-
ability of tumor control, whereas the NTCP function corre-
sponds to the probability of having normal tissue complica-
tions, due to radiotherapy. Finally, the objective function P+
corresponds to the probability of achieving tumor control
without having any normal tissue complications and it was
used as the primary objective function in the optimization of
the different plans.
After defining all the above parameters and functions, seven
treatment plans were produced in order to examine the im-
pact of different factors on the values of the examined radio-
biological measures. For this purpose, the number and type of
OARs involved, the radiobiological parameters of the in-
volved tissues and the tissues included in the ROI were var-
ied. The values of the radiobiological measures (TCP, NTCP,
P+ and Generalized Gamma) were calculated both by the
treatment planning system as well as by an independent
software. This software uses the DVHs files of the target and
OARs (that are exported by RayStation) as input for the cal-
culations of the TCP, NTCP, P+ and Generalized Gamma
values. It has also an internal library with values for the ra-
diobiological parameters of the different tumors and OARs
for different models. These values are exactly the same as
those used by the RayStation treatment planning system.
Treatment planning specification and optimization
using RayStation
In order to illustrate the characteristics of the Generalized
Gamma concept and to identify the accuracy of the
RayStation treatment planning system in calculating the
values of the different related radiobiological measures, a
number of comparisons were performed.
Firstly, the values of Generalized Gamma of the TCP and
NTCP measures were calculated for the case of a heteroge-
neous dose distribution delivered to different tissues. These
values were calculated both by the RayStation treatment
planning system as well as by the independent software. This
comparison was conducted in order to verify the calculated
values of the Generalized Gamma, TCP and NTCP from the
TPS.
For the prostate cancer case that was used, the first treatment
plan that was produced included all the involved tissues
(namely target and OARs) in the same ROI, which means that
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all the organs were meant to receive the same radiation doses.
Furthermore, additional plans were developed, where inde-
pendent ROIs were used and the different organs were irra-
diated with non-uniform dose distributions. In these cases,
the target received the highest dose and the OARs received a
smaller percentage of the target dose.
After the physical optimization of the different treatment
plans, the radiobiological modality of RayStation was used to
calculate the values of TCP, NTCP, P+ as well as the Gener-
alized Gamma values for the target and the OARs. Those
values were subsequently associated with the theoretical
formulae that give the Generalized Gamma value and the
change in response, which follows a small change in the mean
dose (D ). In this study, the mean dose was increased by 5% in
the first treatment plan (all the organs included in the same
ROI) and 5% in the second plan (organs treated as different
ROIs). Equation (2) is valid only for uniform dose distribu-
tions and it gives an approximate solution to the change in
response after a small change in dose.
In order to obtain a more accurate quantification of the
change in response, one should preferably calculate the
γ-value as a function of dose D or P(D). Assuming Poisson
statistics, the response probability for uniform dose is:
0( ) exp( )aDP D N e  ---------------------------Eq. 10
so that the normalized dose response gradient becomes:
( )( ) ( ) ln ( )dP DD D P D a D P DdD      
----------Eq. 11
Since Equation (10) gives )(lnln(ln 0 DPNaD  and
eNo /ln , the normalized dose-response gradient for
non-uniform doses is thus approximately given as:
( ) ( ) ln ( ) ( ln( ln ( )))D P D P D e P D       -----Eq. 12
The relative change in response as a function of the relative
change in dose can thus be approximated as:
( ) ( ) ln ( ) ( ln( ln ( )))DP D P D P D e P DD 
       ---------Eq. 13
or alternatively, if the mean dose D is known
50
( ) ( ) ln ( ) ( ln(ln2))D DP D P D P D eD D 
       -------Eq. 14
In many circumstances, Equation (12) can be further ap-
proximated as:
( ) ( ) ln ( )D P D P D e     -------------------Eq. 15
where, exact equality prevails when P(D)=e-1. Hence, the
approximate relative change in response as a function of the
relative change in dose (Equation (13)) becomes
( ) ( )*ln ( )DP D P D P D eD 
     ------------------Eq. 16
After the accuracy validation of the Generalized Gamma
value calculations with RayStation, an evaluation of practical
merits of Generalized Gamma was performed. For this pur-
pose, the functionality of the concept was studied for the case
of a target volume consisting of two compartments. Firstly,
the target was segregated into 2 compartments receiving
doses, (D-ε) and (D+ε), where ε is the dose variance, and the
corresponding responses are denoted as P1 and P2, respec-
tively. So, according to Equation (16) and assuming that the
responses are governed by Poisson statistics, the Generalized
Gamma will be:
1 21 1 2 2( ) ( ) ( )v vP D P D P D   ---------------------Eq. 17
where, D1 = D - ε and D2 = D + ε, )1(**0*1  DaeNeP ,
)1(**02
 DaeNeP , 21 * PPP  , a = (lnN0 –lnln2)/D50, D50 =
50Gy and 0 eN e  .
Based on those formulas, generalized gamma is given by the
following expression:
(1 ) (1 )
0 0*{ (1 ) ( / 2) (1 ) ( / 2) }aD aDP D a N e D a N e          ---Eq.18
The gradient of the dose-response function is also given by:
(1 ) (1 )
0 0( ) ( )*{ ( / 2) ( / 2) }aD aDDP D P D a N e a N e       ----Eq. 19
In order to calculate the response of both compartments after
a small increase in dose, (ΔD or δ) to get the theoretically
estimated value for the change in response ΔP=P(D+ΔD)-P(D)
the following formulations were used in Equation (17):
)1)*(1*(*0*1
  DaeNeP , )1(*)1(**0 *2   DaeNeP ,
21 *)( PPDDP  ----------Eq. 20
In this study, we used ΔPreal=P(D+δ)-P(D) to represent the
real value of the change in response. An approximate value
for ΔP was calculated using the Equation (2 and 19). Having
calculated both ΔPreal and ΔPapprox., the quantity (ΔPapprox.- ΔP
real)/ΔPreal was plotted as a function of the prescribed dose D.
Finally, the above procedure was repeated assuming that the
responses of the tissues are governed by normal distribution
statistics. For this investigation, the normal cumulative dis-
tribution was employed for specified mean value μ and
standard deviation σ values. In this study, the mean and
standard deviation values were set equal to D50 = 50 Gy and σ
= D50/γ(2π)1/2. The cumulative distribution returns a sigmoidal
function for TCP and NTCP.
Results and Discussions
Taking into account the above basic definitions and formulas,
as well as the calculations and the data from the RayStation
treatment planning system, the theoretical behavior and
merits of the generalized dose-response gradient were inves-
tigated. Additionally, the influence of the organ architecture
(parallel-serial) and the usefulness of the generalized
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dose-response gradient in practical radiobiological treatment
planning by using the RayStation platform were also studied.
Verification of RayStation computations
First, a verification of the calculations of RayStation regarding
the values of the TCP and NTCP quantities was performed
using an independent homemade software. At first, both the
target and the normal tissue were assumed to belong to the
same ROI, whose volume was characterized by the same
radiobiological parameters (Table 1) and for this reason they
both received the same uniform dose. Based on the calcula-
tions shown in the Appendix, the results for the TCP, NTCP
and Generalized Gammas are presented in Table 2.
As it can be noticed in Table 2, the values of TCP and NTCP
are almost identical, which means that the calculations of
RayStation were verified properly. The minor differences
that appear between TCP and NTCP as well as the respective
Generalized Gamma values stem from the fact that
RayStation calculates the value of the objective function P+
using the expression P+=PB(1-PI) instead of P+=PB-PI that was
used by the independent software. The determination of the
optimal solution corresponds to the determination of the
maximum P+ value. At this point, the value of PB is not equal
to that of PI but to the derivative of P+.
TABLE 1: Radiobiological and physical parameters used in the calculation of the TCP and NTCP measures.
D50 (Gy) γ s N0 n (fractions) α/β (Gy) α (Gy-1) β (Gy-2)
50.0 6.0 0.7 1.21x105 30 3.0 0.20 0.0667
D50: Dose in which the response probability is 50%
γ: maximum normalized value of dose-response gradient
α, β: fractionation parameters of LQ-Poisson model
s: relative seriality parameter that characterize the internal organization of the organ
N0: initial number of clonogenic cells for tumors
TABLE 2: Generalized Gamma values for TCP and NTCP.
TCP (%) NTCP (%) Generalized Gamma for TCP Generalized Gamma for NTCP
19.07 19.53 6.75 6.79
TABLE 3: Summary of the results of Plan 1, which was optimized using a single ROI and D50 value for the target and bladder. However, the rest of
the radiobiological parameters of two organs were different.
Organs D50 (Gy) γ α/β (Gy) s TCP (%) NTCP (%) GenGamma
Prostate 60.0 4.2 10.0 - 53.8 - 4.6
Bladder 60.0 3.0 3.0 0.18 - 54.3 4.0
P+ = 24.6%
Subsequently, further experimental treatment plans were
produced in order to examine the behavior of the objective
function P+, as well as the value of Generalized Gamma and in
this way the effectiveness of the system. Based on the fact that
both organs belong to the same ROI, we expect a small dif-
ference in the Generalized Gamma values due to the differ-
ences in γ and α/β values of the target and bladder. Also, the
Generalized Gamma values are a little different due to the
different response probabilities and parameter values. Ac-
cording to our results (Table 3), P+ is not zero, which indicates
that the expression used in RayStation for P+ calculation is P+
= PB (1-PI).
Theoretical and experimental approach of Generalized
Gamma
In Table 4, the results of another case in which the organs at
risk belong to the same ROI as the target, are shown. In this
case, however, there are two OARs and different radiobio-
logical parameters characterize the target and the two OARs.
Furthermore, different physical constraints were imposed
during the development of the two plans (e.g. the minimum
dose to the target was set to 60 Gy in Plan 3). In Table 4 it is
noticed that the NTCP and the generalized gamma have the
same value for both OARs, something that was expected
because they receive exactly the same dose and they have the
same radiobiological parameters.
In Table 5, the RayStation results for the case that the OARs
belong to a ROI that is different than that of the target are
shown. Those results are derived from three treatment plans,
which were optimized using different combinations or organs
involved (prostate, bladder and rectum), different radiobio-
logical parameters and different physical constraints (e.g. the
minimum dose to the target was set to 60 Gy in Plan 3). It can
be seen that when the prescription dose constraint changed,
the response of rectum was affected much more than those of
the target and bladder and this is also reflected on the Gen-
eralized Gamma values.
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TABLE 4: Summary of the results of two treatment plans, which were
optimized using a single ROI for the target and OARs but different
combinations of radiobiological and physical constraints (e.g. mini-
mum dose to the target).
Organs Prostate Bladder Rectum
D50 (Gy) 60.0 80.0 80.0
γ 2.0 2.0 2.0
s - 0.00001 0.00001
α/β (Gy) 10.0 10.0 10.0
PLAN 2
TCP (%) 61.9 - -
NTCP (%) - 11.3 11.3
GenGamma 2.14 1.34 1.34
P+ (%) 48.7
PLAN 3
TCP (%) 72.4 - -
NTCP (%) - 20.0 20.0
GenGamma 1.80 1.89 1.89
P+ (%) 46.3
TABLE 5: Summary of the results of three treatment plans, which
were optimized using different combinations or organs involved
(prostate, bladder and rectum) and different physical parameters (e.g.
minimum dose to the target).
Organs Prostate Bladder Rectum
D50 (Gy) 52.7 60.0 60.0
γ 4.2 3.0 2.2
s - 0.18 1.0
α/β (Gy) 10.0 3.0 3.0
PLAN 1
TCP (%) 95.3 - -
NTCP (%) - - 4.1
GenGamma 0.68 - 0.65
P+ (%) 91.4
PLAN 2
TCP (%) 93.4 - -
NTCP (%) - 1.3 4.2
GenGamma 0.94 0.31 0.66
P+ (%) 88.5
PLAN 3
TCP (%) 95.3 - -
NTCP (%) - 7.3 32.7
GenGamma 0.77 1.27 2.49
P+ (%) 59.6
After specifying the experimental treatment plans at
RayStation and extracting the respective theoretical Gener-
alized Gamma values, we tried to associate the experimental
results for change in response, ΔP, with the theoretical for-
mulae given in Equation (2, 14 and 16). In Tables 6-10, the
results for theoretical and experimental changes in response
probability (ΔPtheor. and ΔPexp.) for each case and correspond-
ing treatment plan, are presented.
For the scenario of the organs within the same ROI (Plan 2 of
Table 4), a set of values for a 5% increase in mean dose was
acquired. Based on the results shown in Table 6, the experi-
mental value of ΔP is closer to that of Equation (2). As a re-
sult, the experimental value can be used in Equation (2) to
calculate the generalized gamma after the increase in dose.
Table 6 shows that the values of the calculated generalized
gamma of the different organs differ, which stems from the
fact that the ΔP values are not identical.
TABLE 6: Comparison of the ΔPexp. and ΔPtheor. values for a 5% increase
in dose. The Generalized Gamma values before and after the change in
dose are also shown. These results stem from Plan 2 of Table 4.
Organs Prostate Bladder Rectum
∆Pexp. (%) 9.75 7.80 7.80
∆Peq.2 (%) 10.69 6.72 6.72
∆Peq.14 (%) 9.10 5.65 6.65
∆Peq.16 (%) 8.74 6.68 6.68
GenGammabefore 2.14 1.34 1.34
GenGammaafter 1.83 1.84 1.84
The same procedure was repeated for the case that the target
organ and the OARs belong to different ROIs (Plan 1 of Table
5) and the results are presented in Tables 7. According to
those results it can be concluded that a 5% change in dose
results in a change in response, which is close to that derived
by Equation (16). This means that the γ(D) can be calculated
using the expression  **)(ln*)()( eDPDPD  .
TABLE 7: Comparison of the ΔPexp. and ΔPtheor. values for a 5% in-
crease in dose. The Generalized Gamma values before and after the
change in dose are also shown. These results stem from Plan 1 of
Table 5.
Organs Prostate Rectum
∆Pexp. (%) 2.02 4.19
∆Peq.2 (%) 3.38 3.25
∆Peq.14 (%) 3.55 2.86
∆Peq.16 (%) 2.61 3.93
GenGammabefore 0.68 0.65
GenGammaafter 0.52 0.79
Calculating the ΔPtheor. for the case that the target organ and
the OARs belong to different ROIs, and applying physics dose
constraints (Plan 2 of Table 5), it is noticed that for 5% change
in dose the change in response, ΔP is close to that given by
Equation (16). The respective results for ΔP and Generalized
Gamma are presented in Table 8.
TABLE 8: Comparison of the ΔPexp. and ΔPtheor. values for a 5% in-
crease in dose. The Generalized Gamma values before and after the
change in dose are also shown. These results stem from Plan 2 of
Table 5.
Organs Prostate Bladder Rectum
∆Pexp. (%) 3.36 2.41 4.23
∆Peq.2 (%) 4.68 1.54 3.28
∆Peq.14 (%) 4.72 1.41 2.84
∆Peq.16 (%) 3.56 2.31 3.94
GenGammabefore 0.94 0.31 0.66
GenGammaafter 0.72 0.46 0.79
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According to the results shown in Tables 4-8 the theoretical
value of response change, ΔP is in good agreement with the
value returned by RayStation providing a verification of the
validity of Equation (16).
The last part of this study concerns the association of the
values of different quantities between RayStation and their
theoretical calculation regarding the behavior of the change
in response, ΔP and the Generalized Gamma for the D50 point
of the dose-response relation. For this purpose, two treatment
plans were developed by optimizing them so that the corre-
sponding TCP and a NTCP values are almost 50%. In these
cases, the behavior of ΔP and that of Generalized Gamma are
shown in Tables 9 and 10, respectively. This was done by
performing the previously described process, which involves
the calculation of ΔPtheor. and the comparison with the re-
spective ΔPexp. value.
As it can be noticed from Tables 9 and 10, the ΔPexp. value is in
quite good agreement with the ΔPtheor. given by Equation (2)
in both cases. This has resulted in the respective Generalized
Gamma values to be almost the same as the initial values
before the increase. In Table 10, the Generalized Gamma
values before and after the change in dose for both plans are
presented both as calculated by RayStation as well as theo-
retically.
TABLE 9: Summary of the results of three treatment plans, which
were optimized using different combinations or organs involved
(prostate, bladder and anterior rectum) and different physical pa-
rameters. Comparison of ΔPtheor. to ΔPexp. for 5% increase in dose.
Upper panel: TCP 50%, Lower panel: NTCP 50%.
Organs Prostate Bladder
D50 (Gy) 60.0 18.4
γ 2.0 2.0
s - 0.00001
α/β (Gy) 10.0 10.0
TCP (%) 49.9 -
NTCP (%) - 35.9
GenGamma 1.64 2.18
P+ (%) 31.4
D50 (Gy) 60.0 15.5
γ 2.0 2.0
s - 0.00001
α/β (Gy) 10.0 10.0
TCP (%) 36.7 -
NTCP (%) - 48.8
GenGamma 1.61 2.19
P+ (%) 18.9
After verifying the experimental with the theoretical value of
Generalized Gamma for the scenario of increasing the mean
dose by 5%, it was noticed that the experimental value of
Generalized Gamma after the dose increase remains almost
the same as the initial one. This is quite important for the
verification of the accuracy of the TPS and its calculations
because by taking into account the D50 and its properties, the
behavior of the Generalized Gamma was shown to be the
expected one.
TABLE 10: Comparison of ΔPtheor. to ΔPexp. for 5% increase in dose.
Upper panel: TCP 50%, Lower panel: NTCP 50%.
Organs Prostate Bladder
PLAN 1
∆Pexper (%) 7.82 10.76
∆Peq.2 (%) 8.20 10.90
∆Peq.14 (%) 13.14 10.81
∆Peq.16 (%) 9.43 9.99
GenGammabefore (theor.) 1.64 2.18
GenGammaafter (theor.) 1.55 2.23
GenGammabefore (exp.) 1.64 2.18
GenGammaafter (exp.) 1.56 2.15
PLAN 2
∆Pexper (%) 7.91 10.99
∆Peq.2 (%) 8.05 10.95
∆Peq.14 (%) 13.16 11.06
∆Peq.16 (%) 10.00 9.52
GenGammabefore (theor.) 1.61 2.19
GenGammaafter (theor.) 1.61 2.20
GenGammabefore (exper.) 1.61 2.19
GenGammaafter (exper.) 1.62 2.05
Relative error of ΔPapprox. for target volume consisting of
two compartments
Before examining the case of bifurcation of target volume into
two compartments and the dependence of ΔPapprox. on the
received dose, the behavior of Generalized Gamma was
studied as a function of ε. As shown in Figure 1, we can notice
that the generalized gamma decreases as the value of ε in-
creases.
FIG. 1: The Generalized Gamma as a function of the dose change, ε.
Figure 1 could be quite comparable with the findings of the
study of Lind et al.17, where γ had been computed for the case
of having different number of clonogens for the two com-
partments as shown in Figure 2.
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FIG. 2: γ(D) for the two compartments of the target receiving doses
D1 and D2 and having N01 and N02 number of clonogens.
Furthermore, the relative error ΔPapprox as a function of dose
has been studied and plotted (Figure 3) for the case of the
target volume consisting of two compartments with N1 and N2
(=N0) number of clonogens receiving doses D1 and D2, re-
spectively. More specifically, the Poisson model was used to
calculate the response P(D) for the two compartments with
doses (D+ε) and (D-ε) and the response P(D+ΔD) for in-
creasing the dose at D by ΔD. In addition, the values of ΔPre-
al=P(D+ΔD)-P(D) and ΔPapprox.=ΔD/D*gamma were calculated
and their relative deviation as a function of the prescribed
dose was plotted. The result is presented in Figure 3, in which
ε = 0 and δ = 1%.
FIG. 3: Relative error of ΔPapprox as function of dose, for ε=0 and δ= 1%
In Figure 3, it can be noticed that the point at which the best
agreement between ΔPreal and ΔPapprox. occurs is the D37 point.
This point corresponds to a 37% response and the relative
difference is 9.76*10-4. That makes sense considering the
behavior of the Poisson model at D37.
Another model was also used for calculating the response, P
in order to plot the relative error of ΔPapprox, expecting more
precise results and smoother curve.  In this case, the re-
sponse P is represented by the normal cumulative distribution
function, which is computed in terms of a special function
called Probit function (error function), for specific mean
value and standard deviation. In this analysis, the mean value
μ = 50Gy and the standard deviation is σ=D50/(γ*(2π)1/2). The
expectation from this calculation is the sigmoidal curve that
represents the response function. For the computation of
ΔPapprox, the calculation of generalized gamma was not need-
ed, due to the fact that the gradient of P is a cumulative den-
sity function (CDF) and tends towards a probability density
function (PDF). Figure 4 shows the behavior of the relative
deviation ΔPapprox as a function of dose, using the Probit (er-
ror) function.
FIG. 4: ΔPapprox as a result of the probit function.
Even with the Gaussian-shaped curve, it can be noticed that
the maximum value of the curve occurs at a dose slightly
higher than 50Gy. Despite that fact, we notice from the fol-
lowing plot (Figure 5) that the best approximation between
ΔPreal and ΔPapprox. appears at D50, which is 4.34*10-4. From
Figure 5 it can be easily concluded that the probit function
gives a smoother curve than the Poisson model and provides a
much better agreement between the ΔPreal and ΔPapprox. quan-
tities.
FIG. 5: The relative deviation of ΔP using probit function, for ε = 0
and δ = 1%.
The results of this study are strongly dependent on the accu-
racy of the radiobiological models and the parameters de-
scribing the dose-response relation of the different tumors
and normal tissues. This accuracy depends on many factors
such as the mathematical formalism of each model, the as-
sumptions on which it is based, the biological mechanisms
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that it accounts for etc. In this way, certain models describe
better the data from certain clinical conditions (e.g. cancer
type, treatment protocol) than other models and the opposite
happens in other cases. Furthermore, the determination of
the model parameters expressing the effective radiosensitivity
of the tissues is subject to uncertainties imposed by the in-
accuracies in the patient setup during radiotherapy, lack of
knowledge of the inter-patient and intra-patient radiosensi-
tivity and inconsistencies in treatment methodology. Con-
sequently, the determined model parameters (such as the D50,
γ and s) and the corresponding dose-response curves are
characterized by confidence intervals.
In the present study, most of the tissue response parameters
have been taken from recently published clinical studies,
where these parameter confidence intervals have been re-
duced significantly. In this study, due to the fact that many
parameters affect the calculation of the TCP/NTCP values
(such as the clinical endpoints of the different tissues, the
treatment protocol etc.) it would not be possible to provide
any global error bars to those values. This could be possible
only if the clinical problem examined was reduced to a very
specific clinical situation where a TCP uncertainty of about
5% is usually expected. However, due to the comparative
nature of the study, this uncertainty in the absolute
knowledge of the expected responses does not affect the
general conclusions of this investigation.
Conclusion
The present analysis indicates that the concept of Generalized
Gamma is very important for the optimization of a treatment
plan because it is a factor that can predict the organ which
will most likely be affected after a change in dose. That is
because the highest change in response is observed for the
organ with the highest Generalized Gamma. Irrespective of
which organ has the highest response, in a given clinical case
the highest change in response after a small change in dose
cannot be predicted with certainty because usually the organ
with the highest TCP or NTCP tend to have the highest
change in response after a small increase in dose. In the sce-
nario of a small change in dose, the organ with the highest
Generalized Gamma factor is most likely the organ that is
affected the most. Another significant finding to be high-
lighted is the agreement between the theoretically calculated
values of TCP, NTCP, P+ and Generalized Gamma with those
from the RayStation treatment planning system.
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Appendix
Generalized Gamma calculations for TCP and NTCP
Using Equation (5), the following formula for voxel response
can be derived:
2
0
*exp( *exp( * ))DP N a D n
    ----------------Eq. A1
where,
50
ln(ln 2)
1 /
ea dD

 
      50
ln(ln 2)e
aD d


     
-------------Eq. A2
d =D/n is the dose per fraction and n is the number of frac-
tions. α and β are the fractionation parameters of the line-
ar-quadratic (LQ) model and account for the early and late
effects expected.22-24 N0 is the initial number of the clonogenic
cells for tumors or the initial number of functional subunits
for healthy tissues. Parameters α and β are specific for every
organ and specific for the kind of injury (endpoint) consid-
ered and can be calculated only from clinical data.
Based on Equation (A1, A2 and 7), the TCP, NTCP and cor-
responding generalized gamma values for the five bin DVH
shown in Table A1 are calculated by the following equations:
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TABLE A1. Radiobiological parameters and calculations of the gen-
eralized gamma for a tumor and a healthy tissue, respectively.
D50
(Gy) γ s
α/β
(Gy) N0
n (frac-
tions)
α
(Gy-1) β (Gy-2)
50 6.0 0.7 3.0 1.21*105 30 0.20 0.0667
Dose V
(Vol)
P PV θP/θDi
*Di
(1-Ps)V θP/θDi
*Di
θP/θPi
50.2 0.250 0.1442 0.6163 10.286 0.9281 0.1182 1.4918
50.4 0.125 0.1556 0.7925 4.7540 0.9611 0.1174 0.7411
50.6 0.250 0.1951 0.6646 8.7868 0.9085 0.1355 1.7149
50.8 0.125 0.2230 0.8289 4.0593 0.9476 0.1425 0.9114
51.0 0.250 0.2521 0.7085 7.4999 0.8869 0.1483 1.9279
TCP
(%)
Generalized
Gamma for TCP NTCP (%)
Generalized
Gamma for NTCP
19.07 6.75 19.53 6.79
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